To keep up-to-date with the latest in regulatory science, follow CIRS on LinkedIn.
For CIRS publications including R&D Briefings, journal articles and reports, please visit the Publications area.
Dr Liberti presents on Facilitated Regulatory Pathways
Last week CIRS Head of Regulatory Collaborations and RAPS board member Dr Lawrence Liberti discussed "Challenges and Opportunities for Using Facilitated Regulatory Pathways (FRPs) in Mature and Emerging Markets" as [...]
Regulatory observations across Latin America
As numerous factors have recently contributed to changes in the regulatory environment, we have been monitoring and analysing structural regulatory issues affecting overall access to medicines in the Latin [...]
COVID-19: what will be the ‘new normal’?
A number of changes to society and the economy have emerged during the COVID-19 pandemic, which are likely to impact regulators, HTA agencies and the pharma industry. CIRS recently hosted [...]
Updated list of CIRS workshops
Unfortunately, given current circumstances, we have had to postpone our June workshop. Please see below for our revised list of workshops. 15-16 September, Bogota, Columbia Effectiveness of the regulatory [...]
CIRS selected as Technical Partner for PQM+ programme
We’re delighted to announce that we’ve been selected as a Technical Resource Partner for the Promoting the Quality of Medicines Plus (PQM+) programme, which is funded by the US Agency [...]
Revised list of CIRS workshops
Unfortunately, given current circumstances, we have had to postpone our March workshop. Please see below for our revised list of workshops. 11-12 June, Tyson's Corner, USA Digital health: exploring the [...]
CIRS Awarded a Grant to Help Accelerate Registration of Medicines in Low and Middle Income Countries
We’re delighted that the Bill and Melinda Gates Foundation is continuing to support our work with medicine regulatory agencies in low- and middle-income countries (LMICs) through the OpERA programme. The [...]
December 2019 Slide of the Month
December's Slide of the Month is taken from a CIRS poster recently presented at ISPOR Europe 2019. Does FDA Breakthrough Designation affect HTA recommendation in terms of timing and outcome? [...]